Why we measure it

Oestradiol and progesterone govern reproductive function, but their systemic influence extends to domains that dominate long-term health risk. Oestradiol maintains bone mineral density by inhibiting osteoclast activity — its decline during menopause is the primary driver of postmenopausal osteoporosis, which affects approximately 50% of women over 50. Oestradiol also maintains endothelial function, favourable lipid metabolism (raising HDL, lowering LDL), and vascular compliance — which explains why premenopausal women have substantially lower cardiovascular risk than age-matched men, and why this risk converges after menopause. In males, oestradiol derived from aromatisation of testosterone plays a critical role in maintaining bone density, libido, cognitive function, and lipid balance; very low oestradiol in males (whether spontaneous or from over-suppression of aromatase) causes bone loss and sexual dysfunction. Excess oestradiol in males — from high aromatase activity associated with visceral obesity — suppresses gonadotropin production, lowers testosterone, and raises cardiovascular risk. Tracking oestradiol and progesterone biannually provides the longitudinal data needed to detect the onset of perimenopause (an erratic oestradiol pattern with rising FSH), monitor the hormonal response to lifestyle or pharmacological interventions, and contextualise symptoms that otherwise appear non-specific.

Why every 6 months

In premenopausal females, oestradiol and progesterone fluctuate dramatically across the menstrual cycle — a single reading has limited interpretive value without specifying cycle day. For consistency, the draw should be timed to a consistent point in the cycle (typically day 2–3 of the cycle for follicular-phase oestradiol and FSH, or day 21 for mid-luteal progesterone confirmation of ovulation). In perimenopausal and postmenopausal women, and in males, cycle-phase specification is not required. The six-month interval captures meaningful hormonal trajectory — the gradual decline of ovarian oestradiol production with ageing, the impact of body composition changes on peripheral aromatisation, and the hormonal response to menopausal hormone therapy or other interventions.

What movement means

Reference ranges for oestradiol and progesterone vary substantially by sex, age, and menstrual cycle phase, and by assay method. The ranges below represent approximate reference values for specific clinical contexts; laboratory-specific values should always be consulted. Oestradiol is reported in pmol/L (SI units) or pg/mL (conventional); progesterone in nmol/L or ng/mL.

In the protocol